EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer

Summary

The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.

Timeline

Start

2023-03-01

Primary completion

2024-01-23

Completion

2024-01-23

Outcome

Outcome not reported

Stopped (Enrollment): “the study recruitment is significantly behind expectations as only one single patient has started treatment”

Drugs

Indications